Indian healthcare stocks experienced a sharp market decline following severe judicial criticism over excessive drug markups and corporate healthcare business practices. The BSE Hospitals Index dropped by 5% as 16 of its 17 constituent members closed lower in late September 2026. This downturn erased approximately 248 billion rupees, equivalent to roughly $2.6 billion, in market value.

Key Market Losses and Judicial Observations

The judicial scrutiny was initiated on September 29, 2026, by a Supreme Court bench comprising Justices Vikram Nath and Sandeep Mehta. The judges expressed severe concern over the vast pricing gap between wholesale procurement costs and final consumer prices for essential medicines. The court characterized these extreme pricing disparities as carnage and dacoity, highlighting the heavy financial burden placed on patients and taxpayers.

Market reaction to the proceedings was swift across major hospital chains. Here is how individual stock prices declined during the downturn:

• Apollo Hospitals Enterprise Ltd. saw its share price fall by 5.7%.
• Fortis Healthcare Ltd. dropped by 6.3%.
• Max Healthcare Institute Ltd. declined by 5.3%.

Mechanisms of Inflated Patient Bills

The Supreme Court examined specific cases where profit margins on essential medications reached extreme levels. These pricing structures directly impact consumer bills and government-funded healthcare programs like Ayushman Bharat. The key financial and regulatory figures highlighted during the proceedings include:

• ₹248 billion or $2.6 billion erased in total market value from Indian hospital stocks.
• ₹3,000 to ₹27,000 price disparity observed for a specific cancer drug supplied to retailers versus sold to patients.
• 16% retailer margin prescribed under the Drugs Prices Control Order of 2013, which the court queried for uniform application.
• 17 constituent members in the BSE Hospitals Index, of which 16 closed lower.

The bench also flagged concerns over private hospitals requiring patients to purchase medicines exclusively from in-house pharmacies. Solicitor General Tushar Mehta, representing the Centre, argued that private hospitals were the primary beneficiaries of these steep markups. The court questioned why the standard 16% retailer margin under the Drugs Prices Control Order, 2013, should not be applied universally to ensure affordability.

Regulatory Next Steps

In a separate directive on pharmaceutical marketing, the Supreme Court instructed the Union government to form a three-member expert committee. This committee will evaluate marketing practices and determine if a statutory framework is necessary to regulate gifts and incentives provided by drugmakers. The Centre is expected to present information regarding pricing mechanisms during the next hearing scheduled for October 12, 2026, while compliance regarding the expert committee will be reviewed on January 29.